CHE Quote, Financials, Valuation and Earnings

Amedisys has a net margin of 12.5% compared to Chemed's net margin of 2.88%. Chemed's return on equity of 26.22% beat Amedisys's return on equity of 7.23%.

Chemed has a consensus price target of $663.67, signalling upside risk potential of 25.27%. On the other hand Amedisys has an analysts' consensus of $96.86 which suggests that it could grow by 6.68%. Given that Chemed has higher upside potential than Amedisys, analysts believe Chemed is more attractive than Amedisys.

Chemed has a beta of 0.474, which suggesting that the stock is 52.593% less volatile than S&P 500. In comparison Amedisys has a beta of 0.719, suggesting its less volatile than the S&P 500 by 28.1%.

Chemed has a quarterly dividend of $0.50 per share corresponding to a yield of 0.34%. Amedisys offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Chemed pays 8.62% of its earnings as a dividend. Amedisys pays out -- of its earnings as a dividend. Chemed's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Chemed quarterly revenues are $606.2M, which are larger than Amedisys quarterly revenues of $587.7M. Chemed's net income of $75.8M is higher than Amedisys's net income of $16.9M. Notably, Chemed's price-to-earnings ratio is 26.77x while Amedisys's PE ratio is 36.03x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Chemed is 3.40x versus 1.29x for Amedisys. Usually stocks with elevated PS ratios are considered overvalued.

Option Care Health has a net margin of 12.5% compared to Chemed's net margin of 4.21%. Chemed's return on equity of 26.22% beat Option Care Health's return on equity of 14.65%.

Chemed has a consensus price target of $663.67, signalling upside risk potential of 25.27%. On the other hand Option Care Health has an analysts' consensus of -- which suggests that it could grow by 29.79%. Given that Option Care Health has higher upside potential than Chemed, analysts believe Option Care Health is more attractive than Chemed.

Chemed has a beta of 0.474, which suggesting that the stock is 52.593% less volatile than S&P 500. In comparison Option Care Health has a beta of 1.314, suggesting its more volatile than the S&P 500 by 31.359%.

Chemed has a quarterly dividend of $0.50 per share corresponding to a yield of 0.34%. Option Care Health offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Chemed pays 8.62% of its earnings as a dividend. Option Care Health pays out -- of its earnings as a dividend. Chemed's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Chemed quarterly revenues are $606.2M, which are smaller than Option Care Health quarterly revenues of $1.3B. Chemed's net income of $75.8M is higher than Option Care Health's net income of $53.9M. Notably, Chemed's price-to-earnings ratio is 26.77x while Option Care Health's PE ratio is 19.50x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Chemed is 3.40x versus 0.85x for Option Care Health. Usually stocks with elevated PS ratios are considered overvalued.

OptimizeRx has a net margin of 12.5% compared to Chemed's net margin of -42.82%. Chemed's return on equity of 26.22% beat OptimizeRx's return on equity of -20.12%.

Chemed has a consensus price target of $663.67, signalling upside risk potential of 25.27%. On the other hand OptimizeRx has an analysts' consensus of $9.79 which suggests that it could grow by 101.35%. Given that OptimizeRx has higher upside potential than Chemed, analysts believe OptimizeRx is more attractive than Chemed.

Chemed has a beta of 0.474, which suggesting that the stock is 52.593% less volatile than S&P 500. In comparison OptimizeRx has a beta of 1.363, suggesting its more volatile than the S&P 500 by 36.342%.

Chemed has a quarterly dividend of $0.50 per share corresponding to a yield of 0.34%. OptimizeRx offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Chemed pays 8.62% of its earnings as a dividend. OptimizeRx pays out -- of its earnings as a dividend. Chemed's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Chemed quarterly revenues are $606.2M, which are larger than OptimizeRx quarterly revenues of $21.3M. Chemed's net income of $75.8M is higher than OptimizeRx's net income of -$9.1M. Notably, Chemed's price-to-earnings ratio is 26.77x while OptimizeRx's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Chemed is 3.40x versus 1.00x for OptimizeRx. Usually stocks with elevated PS ratios are considered overvalued.

Regional Health Properties has a net margin of 12.5% compared to Chemed's net margin of -23.24%. Chemed's return on equity of 26.22% beat Regional Health Properties's return on equity of -489.72%.

Chemed has a consensus price target of $663.67, signalling upside risk potential of 25.27%. On the other hand Regional Health Properties has an analysts' consensus of -- which suggests that it could grow by 315.68%. Given that Regional Health Properties has higher upside potential than Chemed, analysts believe Regional Health Properties is more attractive than Chemed.

Chemed has a beta of 0.474, which suggesting that the stock is 52.593% less volatile than S&P 500. In comparison Regional Health Properties has a beta of 0.953, suggesting its less volatile than the S&P 500 by 4.677%.

Chemed has a quarterly dividend of $0.50 per share corresponding to a yield of 0.34%. Regional Health Properties offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Chemed pays 8.62% of its earnings as a dividend. Regional Health Properties pays out -- of its earnings as a dividend. Chemed's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Chemed quarterly revenues are $606.2M, which are larger than Regional Health Properties quarterly revenues of $4.2M. Chemed's net income of $75.8M is higher than Regional Health Properties's net income of -$982K. Notably, Chemed's price-to-earnings ratio is 26.77x while Regional Health Properties's PE ratio is 0.13x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Chemed is 3.40x versus 0.17x for Regional Health Properties. Usually stocks with elevated PS ratios are considered overvalued.